Rockefeller Initiative (Semper Idem)

The Rockefeller Initiative is a program of the U.S Centers for Disease Control and Prevention (CDC). The initiative was established as the Bioweapon Control Unit (BCU) in 2027, and formally established by an Act of Congress in 2040.

The Initiative is operated by the National Center for Antimicrobial Resistance Research (NCARR), and the Initiative mainly deals with research against viral or bacterial pathogens and microbes resistant against modern medicine. Since its founding in 2027, the Rockefeller Initiative has been involved in the development of 400+ new antibiotic or nanobiotic drugs, and is involved with the Epidemic Preparedness Alliance within the World Health Organization.

Founded as an organization within the Department of Defense to combat the emergence of bioweapons, the highly specialized unit of microbiologists and biochemists became focused on antimicrobial resistance following a severe outbreak of XR -type tuberculosis in southern Ohio.

In 2040, the Initiative was officially created, and named after Rockefeller University, which had shut down in 2034.

The Rockefeller Initiative was crucial in the invention of nanogens, specialized nanorobotic components that could infiltrate and kill a bacterial cell from within, acting similarly to a bacteriophage.

Responses

 * 2020s-present: MRSA, (Methicillin-resistant Staphylococcus aureus) and its subsets. Following an outbreak of MRSA in Oregon in 2033, the Initiative created two new oxazolidines (including a new generation of linezolid drugs) that became widely available and were effective until the late 2050s.
 * 2030s: HIV/AIDS treatment that included specific antiretroviral integrase inhibitors, decreasing the already declining rate of the retrovirus globally.